Morgan Stanley
SNDX icon

Morgan Stanley’s Syndax Pharmaceuticals SNDX Stock Holding History

Morgan Stanley’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.9M Sell
893,933
-181,568
-17% -$3.95M ﹤0.01% 2919
2025
Q4 		$22.6M Sell
1,075,501
-123,795
-10% -$2.16M ﹤0.01% 2823
2025
Q3 		$18.5M Buy
1,199,296
+350,060
+41% +$4.58M ﹤0.01% 2959
2025
Q2 		$7.95M Sell
849,236
-1,432,680
-63% -$15.8M ﹤0.01% 3657
2025
Q1 		$28M Sell
2,281,916
-3,030,906
-57% -$42.7M ﹤0.01% 2348
2024
Q4 		$70.2M Buy
5,312,822
+4,425,677
+499% +$75.7M ﹤0.01% 1527
2024
Q3 		$17.1M Buy
887,145
+130,913
+17% +$2.7M ﹤0.01% 2945
2024
Q2 		$15.5M Sell
756,232
-1,059,526
-58% -$22.2M ﹤0.01% 2944
2024
Q1 		$43.2M Sell
1,815,758
-1,512,854
-45% -$33.7M ﹤0.01% 1891
2023
Q4 		$71.9M Buy
3,328,612
+2,778,583
+505% +$42.7M ﹤0.01% 2061
2023
Q3 		$7.99M Buy
550,029
+120,309
+28% +$2.28M ﹤0.01% 3331
2023
Q2 		$8.99M Sell
429,720
-664,124
-61% -$13.8M ﹤0.01% 3263
2023
Q1 		$23.1M Buy
1,093,844
+944,475
+632% +$23.5M ﹤0.01% 2263
2022
Q4 		$3.8M Sell
149,369
-9,202
-6% -$215K ﹤0.01% 3987
2022
Q3 		$3.81M Sell
158,571
-133,106
-46% -$2.99M ﹤0.01% 3916
2022
Q2 		$5.61M Sell
291,677
-406,024
-58% -$6.76M ﹤0.01% 3662
2022
Q1 		$12.1M Buy
697,701
+420,225
+151% +$7.08M ﹤0.01% 2685
2021
Q4 		$6.07M Buy
277,476
+24,337
+10% +$450K ﹤0.01% 3510
2021
Q3 		$4.84M Buy
253,139
+204,243
+418% +$3.4M ﹤0.01% 3750
2021
Q2 		$839K Sell
48,896
-351
-0.7% -$6.43K ﹤0.01% 5192
2021
Q1 		$1.1M Sell
49,247
-11,988
-20% -$271K ﹤0.01% 4664
2020
Q4 		$1.36M Buy
61,235
+18,362
+43% +$381K ﹤0.01% 4459
2020
Q3 		$633K Sell
42,873
-107,192
-71% -$1.63M ﹤0.01% 4515
2020
Q2 		$2.22M Buy
150,065
+79,301
+112% +$1.21M ﹤0.01% 3500
2020
Q1 		$776K Sell
70,764
-24,977
-26% -$234K ﹤0.01% 4118
2019
Q4 		$841K Buy
95,741
+4,363
+5% +$32K ﹤0.01% 4636
2019
Q3 		$683K Buy
91,378
+30,680
+51% +$279K ﹤0.01% 4520
2019
Q2 		$566K Sell
60,698
-7,381
-11% -$53.8K ﹤0.01% 4542
2019
Q1 		$357K Sell
68,079
-83,417
-55% -$476K ﹤0.01% 4754
2018
Q4 		$675K Sell
151,496
-118,099
-44% -$647K ﹤0.01% 4596
2018
Q3 		$2.18M Buy
269,595
+26,043
+11% +$186K ﹤0.01% 3937
2018
Q2 		$1.71M Buy
243,552
+3,286
+1% +$32.2K ﹤0.01% 4220
2018
Q1 		$3.42M Sell
240,266
-25,335
-10% -$269K ﹤0.01% 3458
2017
Q4 		$2.33M Buy
265,601
+17,687
+7% +$175K ﹤0.01% 3902
2017
Q3 		$2.9M Buy
247,914
+122,699
+98% +$1.5M ﹤0.01% 3522
2017
Q2 		$1.75M Buy
125,215
+5,228
+4% +$59.8K ﹤0.01% 3916
2017
Q1 		$1.65M Buy
119,987
+81,159
+209% +$843K ﹤0.01% 3985
2016
Q4 		$278K Buy
38,828
+20,891
+116% +$229K ﹤0.01% 5215
2016
Q3 		$272K Buy
17,937
+15,819
+747% +$208K ﹤0.01% 4864
2016
Q2 		$20K Sell
2,118
-1,361
-39% -$18.7K ﹤0.01% 5855
2016
Q1 		$46K Buy
+3,479
New +$43.7K ﹤0.01% 5644

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Morgan Stanley's SNDX Position: Q1 2026 in Review

Morgan Stanley reduced its Syndax Pharmaceuticals (SNDX) stake by 17% in Q1 2026, selling an estimated $3.95M and leaving 893,933 shares worth $20.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2919.

Morgan Stanley first reported a position in SNDX in Q1 2016 and has held it in 41 quarters since. The position peaked at $71.9M in Q4 2023. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Morgan Stanley held 893,933 shares of Syndax Pharmaceuticals worth $20.9M as of Q1 2026.
  • Morgan Stanley sold 181,568 Syndax Pharmaceuticals shares in Q1 2026, an estimated $3.95M.
  • Syndax Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #2919 holding.
  • Morgan Stanley first reported a position in Syndax Pharmaceuticals in Q1 2016 and has held it in 41 quarters since.
  • Morgan Stanley's Syndax Pharmaceuticals position peaked at $71.9M in Q4 2023.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.